Denali Therapeutics Inc (DNLI)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$14.40
Buy
$14.91
$-0.21 (-1.42%)
Prices updated at 20 Mar 2025, 23:01 EDT
| Prices minimum 15 mins delay
Prices in USD
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 331m | - | |
| - | - | |
| -197m | -502m | |
| -59.51 | - | |
| -145m | -423m | |
| -180m | -493m | |
| Sales, General and administrative | 103m | 105m |
| Interest expenses | - | - |
| Provision for income taxes | 30,000 | 68,000 |
| Operating expenses | 527m | 502m |
| Income before taxes | -145m | -423m |
| Net income available to common shareholders | -145m | -423m |
| -1.06 | -2.57 | |
| Net interest income | 52m | 65m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -1.06 | -2.57 |
| Free cash flow per share | -2.5546 | -2.4005 |
| Book value/share | 8.0813 | 9.1422 |
| Debt equity ratio | 0.04363 | 0.029823 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 1,064m | 864m |
| Current liabilities | 78m | 102m |
| Total capital | 1,031m | 1,230m |
| Total debt | 52m | 49m |
| Total equity | 1,031m | 1,230m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 1,154m | 1,374m |
| Total liabilities | - | - |
| Cash and cash equivalents | 127m | 175m |
| Common stock | 138m | 144m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 220m | 129m |
| Cash dividends paid | - | - |
| -371m | -364m | |
| Investments (gains) losses | 249m | -89m |
| 129m | 177m | |
| Net income | - | - |
| -358m | -348m | |
| -13m | -16m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
